Effect of magnesium sulfate combined with labetalol on serum sFlt‑1/PlGF ratio in patients with early‑onset severe pre‑eclampsia

Wang,Ying; Bao,Jing; Peng,Min

doi:10.3892/etm.2020.9406

Effect of magnesium sulfate combined with labetalol on serum sFlt‑1/PlGF ratio in patients with early‑onset severe pre‑eclampsia

Authors:
- Ying Wang
- Jing Bao
- Min Peng
View Affiliations

Affiliations: Department of Obstetrics, Maternity and Child Health Care Hospital of Hubei, Wuhan, Hubei 430000, P.R. China
Published online on: October 27, 2020 https://doi.org/10.3892/etm.2020.9406
Article Number: 276
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the therapeutic effect of magnesium sulfate combined with labetalol on the early‑onset severe pre‑eclampsia (ES‑PE) and explore the role of soluble fms‑like tyrosine kinase‑1 (sFlT‑1), placental growth factor (PlGF), and sFlt‑1/PlGF ratio in the treatment. A total of 164 ES‑PE patients admitted to the Maternity and Child Health Care Hospital of Hubei (Wuhan, China) were assigned to this observational study. Among them, 83 patients were enrolled in group A and treated with magnesium sulfate combined with labetalol hydrochloride, and 81 patients were enrolled in group B and treated with magnesium sulfate. The therapeutic effect, adverse reactions and pregnancy outcomes in the two groups were analyzed. Serum sFlt‑1 and PlGF concentrations, before and after treatment, were measured by enzyme‑linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value of pre‑treatment serum sFlt‑1/PlGF ratio for the clinical outcome. The effective rate was significantly higher in group A than that in group B. Group A presented superior pregnancy outcomes over group B. The serum sFlt‑1 concentration and sFlt‑1/PlGF ratio after treatment were significantly lower than those before treatment in groups A and B, whereas PlGF concentration was significantly higher after treatment in both groups. After treatment, group A had markedly lower serum sFlt‑1 concentration and sFlt‑1/PlGF ratio than group B, and markedly higher PlGF concentration than group B. The area under curve (AUC) of serum sFlt‑1/PlGF ratio before treatment for the prediction of the clinical efficacy was 0.737. In conclusion, magnesium sulfate combined with labetalol could be effectively used for the treatment of ES‑PE. The results of ELISA revealed that the balance of sFlT‑1 and PlGF was improved after treatment and the sFlT‑1/PlGF ratio was decreased. The assessment of sFlt‑1/PlGF ratio before treatment was shown to have a certain predictive value for the efficacy of ES‑PE treatment.

View Figures

View References

1	Pilliod RA, Feinberg BB and Burwick RM: Maternal and Feto-placental phenotypes of early-onset severe preeclampsia. J Matern Fetal Neonatal Med. 29:1209–1213. 2016.PubMed/NCBI View Article : Google Scholar
2	Fisher SJ: Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 213 (4 Suppl):S115–S122. 2015.PubMed/NCBI View Article : Google Scholar
3	Yang W, Wang A, Zhao C, Li Q, Pan Z, Han X, Zhang C, Wang G, Ji C, Wang G, et al: miR-125b enhances IL-8 production in early-onset severe preeclampsia by targeting Sphingosine-1-phosphate lyase 1. PLoS One. 11(e0166940)2016.PubMed/NCBI View Article : Google Scholar
4	van Esch JJA, van Heijst AF, de Haan AFJ and van der Heijden OWH: Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J Matern Fetal Neonatal Med. 30:2789–2794. 2017.PubMed/NCBI View Article : Google Scholar
5	He Y, Xu B, Song D, Yu F, Chen Q and Zhao M: Correlations between complement system's activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnanc. 35:499–509. 2016.PubMed/NCBI View Article : Google Scholar
6	Müller A, Horvat V, Vulin M, Mandić S, Šerić V and Vidosavljević D: The soluble Fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia-single institution experience. Med Glas (Zenica). 16:53–59. 2019.PubMed/NCBI View Article : Google Scholar
7	He Y, Xu B, Song D, Yu F, Chen Q and Zhao M: Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. Am J Reprod Immunol. 76:205–211. 2016.PubMed/NCBI View Article : Google Scholar
8	Yusuf AM, Kahane A and Ray JG: First and second trimester serum sFlt-1/PlGF ratio and subsequent preeclampsia: A systematic review. J Obstet Gynaecol Can. 40:618–626. 2018.PubMed/NCBI View Article : Google Scholar
9	Herraiz I, Simón E, Gómez-Arriaga P, Martínez-Moratalla JM, García-Burguillo A, Jiménez EA and Galindo A: Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: An approach for clinical integration. Int J Mol Sci. 16:19009–19026. 2015.PubMed/NCBI View Article : Google Scholar
10	Suzuki H, Hirashima C, Nagayama S, Takahashi K, Yamamoto T, Matsubara S and Ohkuchi A: Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at <32 weeks compared with ≥32 weeks. Pregnancy Hypertens. 12:96–103. 2018.PubMed/NCBI View Article : Google Scholar
11	Caillon H, Tardif C, Dumontet E, Winer N and Masson D: Evaluation of sFlt-1/PlGF ratio for predicting and improving clinical management of pre-eclampsia: Experience in a specialized perinatal care center. Ann Lab Med. 38:95–101. 2018.PubMed/NCBI View Article : Google Scholar
12	Yang K, Dong G, Tian Y and Li J: Effects of compound Danshen injection combined with magnesium sulfate on serum MPO and hs-CRP in patients with severe preeclampsia. Exp Ther Med. 16:167–170. 2018.PubMed/NCBI View Article : Google Scholar
13	Duley L, Gülmezoglu AM, Henderson-Smart DJ and Chou D: Magnesium sulphate and other anticonvulsants for women with Pre-eclampsia. Cochrane Database Syst Rev. 2010(CD000025)2010.PubMed/NCBI View Article : Google Scholar
14	Bain ES, Middleton PF and Crowther CA: Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: A systematic review. BMC Pregnancy Childbirth. 13(195)2013.PubMed/NCBI View Article : Google Scholar
15	Shekhar S, Sharma C, Thakur S and Verma S: Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: A randomized controlled trial. Obstet Gynecol. 122:1057–1063. 2013.PubMed/NCBI View Article : Google Scholar
16	Duley L, Henderson-Smart DJ and Chou D: Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. (CD000128)2010.PubMed/NCBIdoi: 10.1002/14651858.CD000128.
17	Kassie GM, Negussie D and Ahmed JH: Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia. Pharm Pract (Granada). 12(400)2014.PubMed/NCBI View Article : Google Scholar
18	Giannubilo SR, Bezzeccheri V, Cecchi S, Landi B, Battistoni GI, Vitali P, Cecchi L and Tranquilli AL: Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet. 286:637–642. 2012.PubMed/NCBI View Article : Google Scholar
19	Abdel-Hady el-S, Fawzy M, El-Negeri M, Nezar M, Ragab A and Helal AS: Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings? Arch Gynecol Obstet. 282:23–27. 2010.PubMed/NCBI View Article : Google Scholar
20	Chen Q, Sousa JD, Snowise S, Chamley L and Stone P: Reduction in the severity of early onset severe preeclampsia during gestation may be associated with changes in endothelial cell activation: A pathological case report. Hypertens Pregnancy. 35:32–41. 2016.PubMed/NCBI View Article : Google Scholar
21	Romero R, Chaemsaithong P, Tarca AL, Korzeniewski SJ, Maymon E, Pacora P, Panaitescu B, Chaiyasit N, Dong Z, Erez O, et al: Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia-a longitudinal study. J Matern Fetal Neonatal Med. 31:418–432. 2018.PubMed/NCBI View Article : Google Scholar
22	Wen J, Zhang X and Li C: Clinical effect of low molecular weight heparin sodium combined with magnesium sulfate in the treatment of patients with severe preeclampsia. J Coll Physicians Surg Pak. 29:119–122. 2019.PubMed/NCBI View Article : Google Scholar
23	Molvi SN, Mir S, Rana VS, Jabeen F and Malik AR: Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: A prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obste. 285:1553–1562. 2012.PubMed/NCBI View Article : Google Scholar
24	Das M, Chaudhuri PR, Mondal BC, Mitra S, Bandyopadhyay D and Pramanik S: Assessment of serum magnesium levels and its outcome in neonates of eclamptic mothers treated with Low-dose magnesium sulfate regimen. Indian J Pharmacol. 47:502–508. 2015.PubMed/NCBI View Article : Google Scholar
25	Sun CJ, Li L, Li XY, Zhang WY and Liu XW: Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. Arch Gynecol Obstet. 298:125–132. 2018.PubMed/NCBI View Article : Google Scholar
26	Abdelrahman TN, Youssry MA, Radwan AM and Ahmed A: Impact of intravenous infusion of labetalol combined with magnesium sulfate versus hydralazine combined with magnesium sulfate on fetomaternal hemodynamics in severe preeclampsia. Ain Shams J Anesthesiol. 11(5)2019.
27	Lu JF and Nightingale CH: Magnesium sulfate in eclampsia and pre-eclampsia. Clin Pharmacokin. 38:305–314. 2000.PubMed/NCBI View Article : Google Scholar
28	Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K and Wen SW: Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124–128. 2014.PubMed/NCBI View Article : Google Scholar
29	Foidart JM, Schaaps JP, Chantraine F, Munaut C and Lorquet S: Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immunol. 82:106–111. 2009.PubMed/NCBI View Article : Google Scholar
30	Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, et al: Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: Implications for clinical practice. Ultrasound Obstet Gynecol. 45:241–246. 2015.PubMed/NCBI View Article : Google Scholar
31	Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S and Suzuki M: Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 33:422–427. 2010.PubMed/NCBI View Article : Google Scholar
32	Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W and Verlohren S: The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med. 42:61–68. 2014.PubMed/NCBI View Article : Google Scholar
33	Xu B, Charlton F, Makris A and Hennessy A: Antihypertensive drugs methyldopa, labetalol, hydralazine, and clonidine improve trophoblast interaction with endothelial cellular networks in vitro. J Hypertens. 32:1075–1083. 2014.PubMed/NCBI View Article : Google Scholar
34	Xu B, Bobek G, Makris A and Hennessy A: Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor-α inhibited endothelial nitric oxide synthase expression in Endothelial-trophoblast cellular networks. Clin Exp Pharmacol Physiol. 44:421–427. 2017.PubMed/NCBI View Article : Google Scholar